present posit preclin data eortc-nci-aacr
quick read trend strengthen
analyst certif import disclosur see
lower estim compani neg pre-announc dec sales/ep today
octob earn call management guid sales/ep attribut miss recent iphon order cut telegraph
monday fellow iphon compon supplier lower dec outlook blame lower sens unit management also
reduc gm cite lower factori util rf content complex continu increas approach expand
tam continu macro uncertainti coupl disappoint iphon unit keep us sidelin
present posit preclin data eortc-nci-aacr meet
select inhibit potenti add armamentarium ovarian cancer treatment offer potenti larg address
market syro preclin result present eortc-nci-aacr tripl meet demonstr consist propos
mechanism-of-act synergist carboplatin ovarian cancer cell line demonstr greater anti-tumor activ
combin carboplatin xenograft model ovarian cancer either agent alon base preclin data current
phase trial design optimist futur find ovari cancer set current estim
impact revenu believ could import contributor
quick read trend strengthen
look upon better expect sept result higher guidanc report today
signal improv oper disciplin chain quickli strengthen demand backdrop broader sector comp sale
sept rose impress mark strongest read metric eight year sept adjust ep top
street figur maintain view underli health auto part retail space intact top-
line weak categori past year reflect primarili transitori factor today above-plan announc goe
long way support posit call auto part retail
